---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-267550"
form_type: "8-K"
ticker: "PBLS"
cik: "0001657677"
company_name: "Parabilis Medicines, Inc."
filed_at: "2026-06-11T20:12:52+00:00"
generated_at: "2026-06-11T20:21:42.684404+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Regeneron invests $75M in Parabilis at 10% discount to IPO price in concurrent private placement

## Summary
- Purchased 4,166,666 shares at 90% of $20 IPO price ($18/share); total $75M.
- Private placement closed June 11, 2026, alongside IPO.
- Regeneron granted piggyback registration rights on the shares.
- Charter amended to authorize 600M voting and 200M non-voting common shares, eliminate preferred.
- Transaction signals strategic backing from a major biopharma partner.

## SEC filing metadata
- accession: 0001193125-26-267550
- form_type: 8-K
- ticker: PBLS
- cik: 0001657677
- company_name: Parabilis Medicines, Inc.
- filed_at: 2026-06-11T20:12:52+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1657677/000119312526267550/0001193125-26-267550-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1657677/000119312526267550/ck0001657677-20260609.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-267550
- JSON: https://secwatch.observer/filing/0001193125-26-267550.json
- Plain text: https://secwatch.observer/filing/0001193125-26-267550.txt

## Key facts
- Equity Issuances
  Parabilis Medicines, Inc. issued 4,166,666 shares of common stock to Regeneron Pharmaceuticals, Inc. for per share price equal to 90% of the initial public offering ("IPO") price of $20.00 per share.
  - Security: common stock
  - Shares: 4,166,666 shares
  - Purchaser: Regeneron Pharmaceuticals, Inc.
  - Consideration: per share price equal to 90% of the initial public offering ("IPO") price of $20.00 per share
  source text: On June 9, 2026, Parabilis Medicines, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Regeneron Pharmaceuticals, Inc. (“Regeneron”), for the purchase of an aggregate of 4,166,666 shares (the “Shares”) of its voting common stock, par value $0.0001 (“Common Stock”), at a per share price equal to 90% of the initial public offering (“IPO”) price of $20.00 per share, through a private placement financing (the “Private Placement”), which took place concurrently with the IPO of the Company’s Common Stock. The Private Placement closed on June 11, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1657677/000119312526267550/0001193125-26-267550-index.htm
- Governance Changes
  Parabilis Medicines, Inc.: Filed seventh amended and restated certificate of incorporation to authorize capital stock changes, eliminate references to prior series of preferred stock, and authorize undesignated preferred stock (effective 2026-06-11).
  - Change: charter amendment
  - Effective: 2026-06-11
  source text: the Company filed its seventh amended and restated certificate of incorporation (the “Amended and Restated Certificate”) with the Secretary of State of the State of Delaware
  evidence_url: https://www.sec.gov/Archives/edgar/data/1657677/000119312526267550/0001193125-26-267550-index.htm
- Governance Changes
  Parabilis Medicines, Inc.: Amended and restated bylaws to establish procedures for stockholder meetings, advance notice for proposals and nominations, and conform to amended certificate (effective 2026-06-09).
  - Change: bylaw amendment
  - Effective: 2026-06-09
  source text: the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Board and the Company’s stockholders, became effective as of the effectiveness of the Registration Statement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1657677/000119312526267550/0001193125-26-267550-index.htm
- Material Agreements
  Parabilis Medicines, Inc. entered into Stock Purchase Agreement with Regeneron Pharmaceuticals, Inc. valued at aggregate of 4,166,666 shares at 90% of the $20.00 IPO price (effective 2026-06-09).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Regeneron Pharmaceuticals, Inc.
  - Value: aggregate of 4,166,666 shares at 90% of the $20.00 IPO price
  - Effective: 2026-06-09
  source text: On June 9, 2026, Parabilis Medicines, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Regeneron Pharmaceuticals, Inc. (“Regeneron”), for the purchase of an aggregate of 4,166,666 shares (the “Shares”) of its voting common stock, par value $0.0001 (“Common Stock”), at a per share price equal to 90% of the initial public offering (“IPO”) price of $20.00 per share, through a private placement financing (the “Private Placement”), which took place concurrently with the IPO of the Company’s Common Stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1657677/000119312526267550/0001193125-26-267550-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.